A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Rabeprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd
- 22 Sep 2017 Results published in an an Eisai Co Ltd media release.
- 22 Sep 2017 Primary endpoint has been met (Rate of non-recurrence) according to an Eisai Co Ltd media release.
- 22 Sep 2017 According to an Eisai Co Ltd media release, based on the results from this study the company has received the approval of additional dosage and administration in Japan of the proton pump inhibitor Pariet 5 mg Tablets and 10 mg Tablets to administer 10 mg of rabeprazole sodium per dose twice-daily for the maintenance therapy of proton pump inhibitor-resistant reflux esophagitis.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History